The efficacy in heavily treated populations with no other options continues to be astounding. No one can debate that. But in terms of turning this into a front line or second line blockbuster it will never happen until they find a risk mitigation strategy that is not only effective, but is also tested and accepted by the clinical community as safe.
Market Data 
Markets 
AI
